stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Book value per share
PTC Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was −2.6×, compared with −14.3× in fiscal 2024. At the end of the quarter to 30 September 2026 it was −2.3×. Over the past ten years it has ranged from −14.3× (fiscal 2024) to 10.1× (fiscal 2019); the current reading is higher than 36% of that period. PTC Therapeutics, Inc. ranks 577th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | −2.6× | — |
| FY2024 | −14.3× | — |
| FY2023 | −10.9× | — |
| FY2022 | −4.8× | — |
| FY2021 | 0.0× | (99.72%) |
| FY2020 | 7.3× | (27.70%) |
| FY2019 | 10.1× | 34.08% |
| FY2018 | 7.5× | 88.61% |
| FY2017 | 4.0× | 13.67% |
| FY2016 | 3.5× | (47.74%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | −2.3× | — |
| Jun 2026 | −2.0× | — |
| Mar 2026 | −2.2× | — |
| Dec 2025 | −2.6× | — |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| MANE Veradermics Incorporated compare | 20.1× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 19.3× |
| CGON CG Oncology, Inc. compare | 11.7× |
| IMVT Immunovant, Inc. compare | 3.6× |
| COGT Cogent Biosciences, Inc. compare | 3.1× |
| SRRK Scholar Rock Holding Corporation compare | 1.9× |
| KOD Kodiak Sciences Inc. compare | 1.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −0.8× |
| PTCT PTC Therapeutics, Inc. | −2.3× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement